So far only AMACR/racemase has gained wider acceptance as a positive marker of prostate cancer, although is has two well-known limitations: intratumoral heterogeneity, which was confirmed in 45% of our cases, and AMACR-negative carcinomas (Wang et al, 2006; Murphy et al, 2007). This evidence concerns the gene AMACR and prostate cancer.